TrueNexus and the case for B2B health interoperability
Why a hospital-to-insurer data layer is the most undercovered category in MENA healthtech — and how TrueNexus is winning it.
If you look at where MENA healthtech investment has gone in the last three years, you see a barbell: B2C telemedicine on one end, pharmacy delivery on the other. The middle layer — the data and interoperability infrastructure that makes hospitals, clinics, insurers, and labs actually talk to each other — has been largely ignored.
TrueNexus is filling that gap. They process over 2 million patient records monthly across 47 hospital nodes, with a recent expansion to 15 Ministry of Health hospitals in Riyadh and their first international node at Dubai Health Authority.
Why B2B health interop is the right wedge for the region
Three reasons. First, KSA's regulatory environment is hardening fast. The Saudi Health Council is mandating standardized data exchange formats. Hospitals need a way to comply without rebuilding internal systems. TrueNexus is the layer that translates between legacy systems and the new mandate.
Second, the unit economics are excellent. B2C healthtech in the region has CACs that have grown 3-4x in the last two years as paid acquisition gets more crowded. B2B health interop has long sales cycles but contract values in the high six figures, low churn (you don't switch out your data backbone), and clear expansion paths.
Third, the network effect is real. Each hospital that joins makes the platform more valuable for every existing node — more data to query, more workflows to automate, more insurance arrangements to support.
What's next
TrueNexus closed their Series A at $38M post-money in Q1 2025 — a 3.6× step-up from our entry. They're now expanding the integration footprint to Eastern Province and Jeddah, and beginning to license their platform to insurance partners as a B2B SaaS product.
We're particularly excited about their data layer becoming an analytics product for payers — pricing models that today rely on historical claims data could be radically improved by real-time clinical signal.